BCL2 and lung cancer: The miR-630 expression levels were also evaluated in a panel of lung cancer cells to select cells that showed high and a low expression of miR-630 for miR-630 manipulation and to verify whether miR-630 might modulate cisplatin sensitivity by targeting Bcl-2.